MicroRNA-10b与早期乳腺浸润性导管癌的临床及预后研究

发布时间：2018-06-16 19:19

本文选题：早期乳腺浸润性导管癌 + microRNA-b　；参考：《中国现代医学杂志》2017年04期

【摘要】：目的探讨早期乳腺浸润性导管癌中microRNA-10b(mi R-10b)表达与临床指标及预后关系。方法采用原位分子杂交技术,检测305例中早期乳腺浸润性导管癌组织miR-10b表达,采用Pearson χ~2检验分析miR-10b表达在不同临床指标间的差异性;采用Spearman秩和相关分析早期乳腺浸润性导管癌中miR-10b、年龄、淋巴结、雌激素受体α(ERα)、孕激素受体(PR)及人类表皮生长因子受体2(HER-2)之间的相关性。采用Kaplan-Meier法计算累计无瘤生存时间,应用Log-rank检验比较miR-10b不同表达组间无瘤生存时间的差异。结果早期乳腺浸润性导管癌中miR-10b表达与年龄、肿瘤大小和复发转移,差异具有统计学意义(P0.05);与月经状态、临床分期、化疗、放疗及内分泌治疗比较,差异无统计学意义(P0.05)。miR-10b阳性表达与HER-2阳性表达呈正相关,差异有统计学意义(P0.05)。miR-10b表达阴性中位无瘤生存时间较miR-10b表达阳性时间长,两者比较差异有统计学意义(P0.05);淋巴结阴性时miR-10b阴性表达的中位无瘤生存时间较阳性表达长,两者比较差异有统计学意义(P0.05);相反,miR-10b表达在淋巴结阳性中位无瘤生存时间无统计学意义(P0.05)。结论 miR-10b表达水平与早期乳腺浸润性导管癌复发转移相关,特别在无淋巴结转移且miR-10b阳性表达组的中位无瘤生存时间短,预后差。miR-10b阳性表达是早期乳腺浸润性导管癌的预后因素。
[Abstract]:Objective to investigate the relationship between the expression of microRNA-10bmmi R-10b in early invasive ductal carcinoma of breast and the clinical indexes and prognosis. Methods the expression of miR-10b in 305 cases of breast invasive ductal carcinoma was detected by in situ hybridization. The difference of miR-10b expression among different clinical indexes was analyzed by Pearson 蠂 2 test. The correlation between miR-10b, age, lymph node, estrogen receptor 伪 -ER 伪, progesterone receptor (PRP) and human epidermal growth factor receptor (2HER-2) in early invasive ductal carcinoma of breast was analyzed by Spearman rank sum correlation. Kaplan-Meier method was used to calculate the cumulative tumor-free survival time, and Log-rank test was used to compare the difference of tumor-free survival time among different miR-10b expression groups. Results the expression of miR-10b was significantly different from age, tumor size, recurrence and metastasis in early breast invasive ductal carcinoma (P 0.05), and compared with menstrual status, clinical stage, chemotherapy, radiotherapy and endocrine therapy. There was no significant difference between the positive expression of P0.05, miR-10b and the positive expression of HER-2. There was a significant difference between the positive expression of HER-2 and the positive expression of HER-2. The median tumor-free survival time of the negative expression of P0.05, miR-10b was longer than that of the positive expression of miR-10b. The median tumor-free survival time of miR-10b negative expression in lymph node negative was longer than that of positive expression. The difference between the two groups was statistically significant (P 0.05), whereas the expression of miR-10b was not significant in lymph node positive median tumor-free survival time (P 0.05). Conclusion the expression level of miR-10b is associated with the recurrence and metastasis of early invasive ductal carcinoma of the breast, especially in the group with no lymph node metastasis and miR-10b positive expression. Poor prognosis. MiR-10b positive expression is the prognostic factor of early invasive ductal carcinoma of breast.
【作者单位】：新疆医科大学第一附属医院乳腺外科;
【基金】：新疆重大疾病医学重点实验室专项(No:SKLI-XJMDR-ZX-2014-1)
【分类号】：R737.9

【参考文献】